MedTrace Logo

An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients

NCT02062294 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2017-07-05

Study results available
· View outcomes & findings →

Summary

This retrospective review will evaluate the efficacy of Valcyte (valganciclovir) in preventing Cytomegalovirus (CMV) disease in D+/R- liver transplant recipients. Data from eligible patients will be collected for the 6 months following transplantation.

Conditions

  • Cytomegalovirus Infections

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02062294 on ClinicalTrials.gov